MAIA (MAIA Biotechnology) Accumulated Depreciation: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAIA MAIA Biotechnology Inc MAIA
35 GF Score
Price $1.37
! 1 Warning Sign
View Full Analysis

What is MAIA Biotechnology Accumulated Depreciation?

MAIA Biotechnology MAIA +4.20% 35 Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus rates MAIA with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

MAIA Biotechnology Accumulated Depreciation Related Terms

MAIA Biotechnology Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for MAIA Biotechnology's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MAIA Biotechnology Accumulated Depreciation Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

MAIA Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MAIA
35GF Score
MAIA Biotechnology Inc MAIA
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MAIA Biotechnology Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
MAIA Biotechnology (MAIA) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on MAIA Biotechnology and its competitors.
Is MAIA Biotechnology's Accumulated Depreciation too high?
MAIA Biotechnology's current Accumulated Depreciation is $0.00 Mil. Overall, MAIA Biotechnology has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does MAIA Biotechnology's Accumulated Depreciation compare to TENX and GOSS?
MAIA Biotechnology's Accumulated Depreciation of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on MAIA Biotechnology and its competitors. MAIA Biotechnology's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MAIA Biotechnology stock overvalued right now?
MAIA Biotechnology (MAIA) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. MAIA Biotechnology's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For MAIA Biotechnology (MAIA), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MAIA Biotechnology Business Description

Address 444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
35GF Score

Get the complete analysis for MAIA

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.37
Price